Company: RPTX
Filing Date: 2025-11-17
Form Type: DEFA14A
Source: 0001193125-25-284040
Chunk: 26

Company: Repare Therapeutics Inc.
Filing Date: 2025-11-17
Form: DEFA14A
Chunk 26
---
 and Exchange Commission; |

| (jjjjj) | “SEC Clearance Period” means the number of calendar days between the date the Company                                                                                    
 receives comments from the SEC with respect to the Circular and the date the Company receives confirmation from the SEC that it has no further comments on the Circular; |

| (kkkkk) | “Securities Authorities” means the AMF and the SEC; |

| (lllll) | “Securities Laws” means all Canadian Securities Laws and applicable securities laws of the                                                                                                                                                                
 United States (and the respective regulations made thereunder, together with applicable published fee schedules, prescribed forms, policy statements, notices, orders, blanket rulings and other regulatory instruments of the Securities Authorities, as 
 applicable) and all rules and policies of the Nasdaq;                                                                                                                                                                                                     |

| (mmmmm) | “Securityholders” means, collectively, the Shareholders, and the holders of Incentive 
 Securities;                                                                           |

| (nnnnn) | “SEDAR+” means the System for Electronic Data Analysis and Retrieval+; |

| (ooooo) | “Shareholders” means the holders of Common Shares; |

| (ppppp) | “Subsidiary” means Repare Therapeutics USA Inc., a company governed by the laws of the State 
 of Delaware;                                                                                 |

| (qqqqq) | “Superior Proposal” means an unsolicited bona fide written Acquisition Proposal from                                                                                                                                                         
 an arm’s length third person or group of persons acting jointly or in concert made after the date of this Agreement to acquire not less than all of the Common Shares (other than Common Shares beneficially owned by the person making such 
 Acquisition Proposal) or all or substantially all of the assets of the Company on a consolidated basis that:                                                                                                                                 |

| (i) | did not result from a breach of Section 6.1 or any agreement between the person making such Acquisition 
 Proposal and the Company;                                                                               |

| (ii) | complies with all applicable Laws; |

| (iii) | is not subject to a financing condition or contingency and in respect of which the Board of Directors has                                                                                                                                                
 determined in good faith (after consultation with its financial advisors) is fully funded or that adequate arrangements have been made to ensure that the required funds or other consideration will be available to complete such Acquisition Proposal; |

| (iv) | is not subject to any due diligence or access condition; and |

| (v) | the Board of Directors has determined in good faith (